Literature DB >> 25198261

Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage.

Jon Trærup Andersen1, Nadia Lyhne Andersen, Henrik Horwitz, Henrik Enghusen Poulsen, Espen Jimenez-Solem.   

Abstract

OBJECTIVE: To investigate whether exposure to selective serotonin reuptake inhibitors (SSRIs) in early pregnancy is associated with miscarriage.
METHODS: This was a nationwide cohort study identifying all registered pregnancies in Denmark from 1997 to 2010. All births were identified using the Medical Birth Registry, and all records of induced abortion or miscarriage were gathered from the National Hospital Register. Data on SSRI use were gathered from the National Prescription Register. Cox proportional hazard regression models were used to calculate the hazard of miscarriage in women exposed to an SSRI in early pregnancy and the hazard of miscarriage in women discontinuing treatment before pregnancy.
RESULTS: We identified 1,279,840 pregnancies (911,569 births, 142,093 miscarriages, 226,178 induced abortions). Of the 22,884 exposed to an SSRI during the first 35 days of pregnancy, 12.6% (2,883) ended in miscarriage compared with 11.1% among unexposed. The adjusted hazard ratio of having a miscarriage after exposure to an SSRI was 1.27 (95% confidence interval [CI] 1.22-1.33) compared with unexposed. Women discontinuing SSRI treatment 3-12 months before pregnancy also had an increased hazard ratio of having a miscarriage compared to unexposed (1.24, 95% CI 1.18-1.30).
CONCLUSION: Women exposed to SSRIs during early pregnancy were at increased risk of miscarriage as were women discontinuing SSRI treatment before pregnancy, and these risks were similar. Therefore, treatment with SSRIs during pregnancy should not be discontinued as a result of fear of miscarriage. LEVEL OF EVIEDENCE:: II.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25198261     DOI: 10.1097/AOG.0000000000000447

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  12 in total

1.  Most Frequently Reported Prescription Medications and Supplements in Couples Planning Pregnancy: The LIFE Study.

Authors:  Kristin Palmsten; Katrina F Flores; Christina D Chambers; Lauren A Weiss; Rajeshwari Sundaram; Germaine M Buck Louis
Journal:  Reprod Sci       Date:  2017-04-12       Impact factor: 3.060

2.  Urinary selective serotonin reuptake inhibitors across critical windows of pregnancy establishment: a prospective cohort study of fecundability and pregnancy loss.

Authors:  Lindsey A Sjaarda; Jeannie G Radoc; Kerry S Flannagan; Sunni L Mumford; Keewan Kim; Neil J Perkins; Robert M Silver; Enrique F Schisterman
Journal:  Fertil Steril       Date:  2020-10-14       Impact factor: 7.329

Review 3.  [Affective disorders during pregnancy : Therapy with antidepressants and mood stabilizers].

Authors:  N Bergemann; W E Paulus
Journal:  Nervenarzt       Date:  2016-09       Impact factor: 1.214

Review 4.  Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence.

Authors:  Sura Alwan; Jan M Friedman; Christina Chambers
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

Review 5.  Depression and Anxiety During Pregnancy: Evaluating the Literature in Support of Clinical Risk-Benefit Decision-Making.

Authors:  Katharine Baratz Dalke; Amy Wenzel; Deborah R Kim
Journal:  Curr Psychiatry Rep       Date:  2016-06       Impact factor: 5.285

6.  Selective serotonin reuptake inhibitor use patterns among commercially insured US pregnancies (2005-2014).

Authors:  Julie M Petersen; Daina B Esposito; Martha M Werler
Journal:  Arch Womens Ment Health       Date:  2020-03-28       Impact factor: 3.633

7.  The effect of antidepressants on fertility.

Authors:  Marianne M Casilla-Lennon; Samantha Meltzer-Brody; Anne Z Steiner
Journal:  Am J Obstet Gynecol       Date:  2016-01-28       Impact factor: 8.661

8.  Dispensing patterns of selective serotonin reuptake inhibitors before, during and after pregnancy: a 16-year population-based cohort study from the Netherlands.

Authors:  Nina Maren Molenaar; Mijke Pietertje Lambregtse-van den Berg; Gouke Jacobus Bonsel
Journal:  Arch Womens Ment Health       Date:  2019-02-14       Impact factor: 3.633

Review 9.  Optimizing the treatment of mood disorders in the perinatal period.

Authors:  Samantha Meltzer-Brody; Ian Jones
Journal:  Dialogues Clin Neurosci       Date:  2015-06       Impact factor: 5.986

10.  Obstetric outcomes in pregnant women with and without depression: population-based comparison.

Authors:  Hui-Chun Huang; Fung-Chang Sung; Pei-Chun Chen; Cherry Yin-Yi Chang; Chih-Hsin Muo; Huei-Sheng Shiue; Jian-Pei Huang; Tsai-Chung Li; Ya-Ling Tzeng; Shu-I Wu
Journal:  Sci Rep       Date:  2017-10-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.